Us2.ai Selected as Echocardiography AI Algorithm in Alnylam and Viz.ai's AI-Enabled ATTR-CM Care Pathway
Us2.ai has been selected as the echocardiography AI algorithm powering Alnylam and Viz.ai's strategic collaboration to build an AI-enabled ATTR-CM care pathway — designed to help clinicians identify patients earlier in the course of disease and guide appropriate diagnostic evaluation and referral.
The pathway combines Us2.ai's FDA-cleared echocardiography AI with electronic health record connectivity and integration into routine clinical practice.
At the centre of the collaboration is the AWARE study — one of the first prospective, multi-system implementation studies evaluating how AI-enabled echocardiographic screening can be embedded into everyday clinical workflows, and its impact on diagnostic timelines, care coordination, and clinical decision-making in ATTR-CM.
ATTR-CM is a progressive and life-threatening cause of heart failure that remains significantly underdiagnosed, with an estimated 80% of patients worldwide yet to receive a diagnosis. Earlier identification is critical to enabling access to treatment and improving patient outcomes.
The initiative will launch at five pilot US health systems later in 2026, with the goal of generating real-world evidence to support broader adoption across the Viz.ai network.
Read full press release from Alnylam →
Read the full press release from Viz.ai →